<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00544362</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000564075</org_study_id>
    <secondary_id>FFCD-0505</secondary_id>
    <secondary_id>EU-20756</secondary_id>
    <secondary_id>EUDRACT-2006-004770-27</secondary_id>
    <secondary_id>MERCK-FFCD-0505</secondary_id>
    <nct_id>NCT00544362</nct_id>
  </id_info>
  <brief_title>Fluorouracil, Cisplatin, Cetuximab, and Radiation Therapy in Treating Patients With Esophageal Cancer That Can Be Removed by Surgery</brief_title>
  <official_title>Neoadjuvant Treatment for Operable Esophageal Cancer With 5-fluorouracil, Cisplatin, and Cetuximab and Concurrent Radiotherapy: Phase I/II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federation Francophone de Cancerologie Digestive</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federation Francophone de Cancerologie Digestive</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways.&#xD;
      Some block the ability of tumor cells to grow and spread. Others find tumor cells and help&#xD;
      kill them or carry tumor-killing substances to them. Radiation therapy uses high-energy&#xD;
      x-rays to kill tumor cells. Giving fluorouracil and cisplatin together with cetuximab and&#xD;
      radiation therapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of fluorouracil and&#xD;
      cisplatin when given together with cetuximab and radiation therapy in treating patients with&#xD;
      esophageal cancer that can be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the maximum tolerated dose of fluorouracil and cisplatin when administered&#xD;
           with cetuximab concurrently with esophageal radiotherapy. (Phase I)&#xD;
&#xD;
        -  To determine the complete histological response rate (after surgical resection). (Phase&#xD;
           II)&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine progression-free survival and overall survival. (Phase II)&#xD;
&#xD;
        -  To determine the rate of resection with negative margins (R0). (Phase II)&#xD;
&#xD;
        -  To determine the overall tolerance to neoadjuvant therapy. (Phase II)&#xD;
&#xD;
        -  To determine the postoperative morbidity and mortality. (Phase II)&#xD;
&#xD;
      OUTLINE: This is a multicenter study. This is a dose-escalation study of cisplatin and&#xD;
      fluorouracil.&#xD;
&#xD;
      Patients receive cetuximab IV over 2 hours on day -7, then IV over 1 hour on days 1, 8, 15,&#xD;
      22, and 29. Patients also receive cisplatin IV over 1 hour on day 1 or 2 and fluorouracil IV&#xD;
      continuously on days 1-4, 8-11, 15-18, 22-25, and 29-32. Patients undergo radiotherapy 5 days&#xD;
      a week for 5 weeks, beginning on day 1 of chemotherapy. Treatment continues in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients undergo surgery within 6-8 weeks after completion of chemoradiotherapy.&#xD;
&#xD;
      After completion of study therapy, patients are followed at 1 month, every 4 months for 2&#xD;
      years, and then every 6 months for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete histologic response</measure>
    <time_frame>After Surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerance to neoadjuvant therapy</measure>
    <time_frame>From Inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free and overall survival</measure>
    <time_frame>From inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>From Inclusion</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly cetuximab (400 mg/m2 one week before start of radiotherapy RT and 250 mg/m2 during radiotherapyRT), and 5 FU (500 mg/m2 per day D1-D4) combined with cisplatin CDDP (40 mg/m2 D1) on week 1 and 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <arm_group_label>Neoadjuvant chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <arm_group_label>Neoadjuvant chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <arm_group_label>Neoadjuvant chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <arm_group_label>Neoadjuvant chemoradiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Histologically confirmed epidermoid or glandular carcinoma of the thoracic esophagus&#xD;
&#xD;
               -  Invasive disease&#xD;
&#xD;
               -  Only Siewert type I gastroesophageal carcinoma allowed&#xD;
&#xD;
          -  Resectable disease&#xD;
&#xD;
               -  T1N+, T2N0, T2N+, T3N0, or T3N+ (stage II or III)&#xD;
&#xD;
               -  No visceral metastases or mediastinal extensions compromising resectability&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Inoperable disease&#xD;
&#xD;
          -  Invasion of the tracheo-bronchial tree&#xD;
&#xD;
          -  Recurring esophageal paralysis&#xD;
&#xD;
          -  Esopho-tracheal fistula&#xD;
&#xD;
          -  Cervical esophageal carcinoma (&lt; 19 cm above the dental arches)&#xD;
&#xD;
          -  Multifocal esophageal carcinoma&#xD;
&#xD;
          -  Superficial esophageal carcinoma (T1N0)&#xD;
&#xD;
          -  Esophageal carcinoma in the lymph nodes that cannot be included in the radiotherapy&#xD;
             field or cannot be completely surgically resected&#xD;
&#xD;
          -  Proven metastatic disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  WHO performance status 0-1&#xD;
&#xD;
          -  Weight loss &lt; 15%&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm3&#xD;
&#xD;
          -  Creatinine ≤ 1.25 times upper limit of normal&#xD;
&#xD;
          -  PTT ≥ 80%&#xD;
&#xD;
          -  Albumin ≥ 35 g/L&#xD;
&#xD;
          -  FEV1 &gt; 1 L&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients of must use effective contraception&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Known liver cirrhosis&#xD;
&#xD;
          -  Renal insufficiency&#xD;
&#xD;
          -  Respiratory insufficiency (i.e., severe dyspnea at rest or oxygen dependence)&#xD;
&#xD;
          -  Progressive coronary insufficiency&#xD;
&#xD;
          -  Myocardial infarction in the past 6 months&#xD;
&#xD;
          -  Legally incapacitated&#xD;
&#xD;
          -  Impossible to receive study therapy due to geographical, social, or psychological&#xD;
             reasons&#xD;
&#xD;
          -  Noncompliant within constraints of the study&#xD;
&#xD;
          -  Hematologic malignancy or other cancer except carcinoma in situ of the uterine cervix,&#xD;
             treated nonmelanoma skin cancer, or intramucous disease treated within the past 3&#xD;
             years&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Prior anticancer chemotherapy or radiotherapy&#xD;
&#xD;
          -  Treatment with endoprosthesis&#xD;
&#xD;
          -  Surgery (esophagectomy) planned without thoracotomy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martina Schneider</last_name>
    <role>Study Chair</role>
    <affiliation>Federation Francophone de Cancerologie Digestive</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Andre</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR Clermont Ferrand, Hotel Dieu</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63058</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Du Bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federation Francophone de Cancerologie Digestive</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospital Universitaire Hop Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional de Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>October 13, 2007</study_first_submitted>
  <study_first_submitted_qc>October 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2007</study_first_posted>
  <last_update_submitted>May 27, 2016</last_update_submitted>
  <last_update_submitted_qc>May 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the esophagus</keyword>
  <keyword>squamous cell carcinoma of the esophagus</keyword>
  <keyword>stage IIIA esophageal cancer</keyword>
  <keyword>stage IIIB esophageal cancer</keyword>
  <keyword>stage IIIC esophageal cancer</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

